Cargando…
Expression of p53 & epidermal growth factor receptor in glioblastoma
BACKGROUND & OBJECTIVES: Glioblastoma (GB) is the most frequent brain tumour, manifesting at any age, with a peak incidence between 45 and 75 years. Primary and secondary GBs constitute relatively distinct disease entities in evolution, in expression profiles and in therapeutic response. Histopa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926345/ https://www.ncbi.nlm.nih.gov/pubmed/29664032 http://dx.doi.org/10.4103/ijmr.IJMR_1179_15 |
_version_ | 1783318884609163264 |
---|---|
author | Karnam, Sameera Kottu, Radhika Chowhan, Amit Kumar Bodepati, Prasad Chandramouleswara |
author_facet | Karnam, Sameera Kottu, Radhika Chowhan, Amit Kumar Bodepati, Prasad Chandramouleswara |
author_sort | Karnam, Sameera |
collection | PubMed |
description | BACKGROUND & OBJECTIVES: Glioblastoma (GB) is the most frequent brain tumour, manifesting at any age, with a peak incidence between 45 and 75 years. Primary and secondary GBs constitute relatively distinct disease entities in evolution, in expression profiles and in therapeutic response. Histopathologically, primary and secondary GBs are indistinguishable. The aim of this investigation was to study the immunohistochemical (IHC) expression of p53 and epidermal growth factor receptor (EGFR) in GB with the objective of categorizing the morphological variants of GB into primary and secondary based on the presence of low-grade areas and knowing the variable expression of p53 and EGFR in primary and secondary GB. METHODS: A total of 28 patients with GB were studied and categorized into primary and secondary based on the presence of low-grade areas, i.e. discernible astrocytic morphology, gemistocyte and oligodendroglia. Tumours with the presence of combination of the above features or any one of the above features were taken as secondary GB, whereas tumours with highly pleomorphic areas were considered as primary GB. IHC was done on the representative tissue blocks for p53 and EGFR. RESULTS: Majority of the patients were in the fifth and sixth decades of life with a mean age of 46.96±13 yr with male preponderance (male:female 2.5:1). Mean age of presentation was 48.93±12 yr in primary and 44.69±15 yr in secondary GB. All cases of GB were classified into primary (53.57%) and secondary (46.43%) based on morphology. EGFR was more frequently expressed than p53. Based on IHC, 50 per cent of cases were classified into primary, three per cent into secondary and 47 per cent as unclassified. INTERPRETATION & CONCLUSIONS: Histopathological features, i.e. presence of low-grade areas, may play a role in classifying GB into primary and secondary. EGFR has a pivotal role in gliomagenesis. Combination of p53 and EGFR alone may not be sufficient to clarify GB into primary and secondary. |
format | Online Article Text |
id | pubmed-5926345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59263452018-05-08 Expression of p53 & epidermal growth factor receptor in glioblastoma Karnam, Sameera Kottu, Radhika Chowhan, Amit Kumar Bodepati, Prasad Chandramouleswara Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Glioblastoma (GB) is the most frequent brain tumour, manifesting at any age, with a peak incidence between 45 and 75 years. Primary and secondary GBs constitute relatively distinct disease entities in evolution, in expression profiles and in therapeutic response. Histopathologically, primary and secondary GBs are indistinguishable. The aim of this investigation was to study the immunohistochemical (IHC) expression of p53 and epidermal growth factor receptor (EGFR) in GB with the objective of categorizing the morphological variants of GB into primary and secondary based on the presence of low-grade areas and knowing the variable expression of p53 and EGFR in primary and secondary GB. METHODS: A total of 28 patients with GB were studied and categorized into primary and secondary based on the presence of low-grade areas, i.e. discernible astrocytic morphology, gemistocyte and oligodendroglia. Tumours with the presence of combination of the above features or any one of the above features were taken as secondary GB, whereas tumours with highly pleomorphic areas were considered as primary GB. IHC was done on the representative tissue blocks for p53 and EGFR. RESULTS: Majority of the patients were in the fifth and sixth decades of life with a mean age of 46.96±13 yr with male preponderance (male:female 2.5:1). Mean age of presentation was 48.93±12 yr in primary and 44.69±15 yr in secondary GB. All cases of GB were classified into primary (53.57%) and secondary (46.43%) based on morphology. EGFR was more frequently expressed than p53. Based on IHC, 50 per cent of cases were classified into primary, three per cent into secondary and 47 per cent as unclassified. INTERPRETATION & CONCLUSIONS: Histopathological features, i.e. presence of low-grade areas, may play a role in classifying GB into primary and secondary. EGFR has a pivotal role in gliomagenesis. Combination of p53 and EGFR alone may not be sufficient to clarify GB into primary and secondary. Medknow Publications & Media Pvt Ltd 2017-12 /pmc/articles/PMC5926345/ /pubmed/29664032 http://dx.doi.org/10.4103/ijmr.IJMR_1179_15 Text en Copyright: © 2017 Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Karnam, Sameera Kottu, Radhika Chowhan, Amit Kumar Bodepati, Prasad Chandramouleswara Expression of p53 & epidermal growth factor receptor in glioblastoma |
title | Expression of p53 & epidermal growth factor receptor in glioblastoma |
title_full | Expression of p53 & epidermal growth factor receptor in glioblastoma |
title_fullStr | Expression of p53 & epidermal growth factor receptor in glioblastoma |
title_full_unstemmed | Expression of p53 & epidermal growth factor receptor in glioblastoma |
title_short | Expression of p53 & epidermal growth factor receptor in glioblastoma |
title_sort | expression of p53 & epidermal growth factor receptor in glioblastoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926345/ https://www.ncbi.nlm.nih.gov/pubmed/29664032 http://dx.doi.org/10.4103/ijmr.IJMR_1179_15 |
work_keys_str_mv | AT karnamsameera expressionofp53epidermalgrowthfactorreceptoringlioblastoma AT kotturadhika expressionofp53epidermalgrowthfactorreceptoringlioblastoma AT chowhanamitkumar expressionofp53epidermalgrowthfactorreceptoringlioblastoma AT bodepatiprasadchandramouleswara expressionofp53epidermalgrowthfactorreceptoringlioblastoma |